Strains of Pseudomonas aeruginosa isolated from clinical material were very variable in their sensitivity to the bactericidal action of normal serum mediated by the complement system. Fifty per cent killing end points ranged from 0.015 ml to greater than 0.4 ml. Most of the strains with relatively greater sensitivity to serum were isolated from patients with cystic fibrosis. Immunization of rabbits resulted in antisera with enhanced levels of bactericidal antibody, except with one strain which was resistant to the bactericidal action of normal serum and antiserum. When P. aeruginosa was cultivated at 41 C instead of at 37 C, it was significantly more sensitive to serum and to several antibiotics, thereby implicating fever as a host defense mechanism in Pseudomonas infections. In contrast to their heterogeneity to serum bactericidal activity, the strains were relatively homogeneous in their sensitivity to polymyxin, with no apparent association between their sensitivity to the two antimicrobial agents.
The importance of Pseudomonas aeruginosa as a human pathogen has apparently increased in recent years, possibly because of a wider interest in "opportunistic" bacterial infections, the increasing complexity of modern medical apparatus, and the fact that the organism is relatively resistant to most of the antibiotics in common use and to many antiseptics (5) . After severe burns and leukemia, P. aeruginosa may cause a fatal generalized infection and frequently it is found as a pulmonary complication of cystic fibrosis. Nonetheless, the lethal factor of Pseudomonas infection has not been elucidated (2) . Immunization with a carbohydrate fraction from the slime layer of the organism has induced protection in mice (1) .
Because of the possible significance of the complement system as a mechanism of host defense against P. aeruginosa, the sensitivity of different strains of this organism to the bactericidal action of normal and immune sera was determined. Moreover, the pseudomonicidal effects of serum, in association with antibiotics with different mechanisms of action, were determined as were the effects of the antibiotics themselves. In addition, since differences in the cultivation temperature have a profound effect on the serum sensitivity of certain bacteria (10), the P. aeruginosa strains were cultivated and allowed to react with serum and other antimicrobial agents at temperatures above and below 37 C.
MATERIALS AND METHODS Bacteria. Seven different strains of P. aeruginosa were used in the initial studies. Three of these strains are designated PD-05074 (isolated from a urinary tract infection), LA-3399 (isolated from a wound infection), and 74C-1 (source unknown); they are of serotypes 3, 1, and 2, respectively, and probably represent some of the most commonly occurring types in man. The other strains, TIR-43 (nonmucoid), TIR-60 (nonmucoid), TIR-55 (mucoid), and TIR-59 (mucoid), were isolated from cystic fibrosis patients. Sixteen additional strains of four different serotypes from different sources (Table 2) Antigens and antisera. A heptavalent antigen composed of about 0.12 mg of lipopolysaccharide (dry weight) per ml from each of the seven serotypes provided a final preparation of 0.85 mg of lipopolysaccharide. Each of the antigens was prepared from the dried organism by extraction with trichloroacetic acid (11) . Rabbit antiserum to this heptavalent antigen was prepared by subcutaneous injection of 0.3 ml of the antigen, followed 8 days later by a similar injection of 0.7 ml, and collection of blood 6 days after the second injection. Antisera to the individual P. aeruginosa strains were prepared by subcutaneously injecting 5% of the growth (18 hr) of each organism in a petri plate (diameter, 9 cm) on meat extract agar (7) suspended in 0.85% NaCl; 37 days later the rabbits were injected similarly with 6.5% of the growth on a 453 (Table 1 ). The 50% end points ranged from 0.014 ml of normal human serum and 0.072 ml of normal guinea pig serum for strain TIR-59 to about 0.4 ml of human serum and greater than 0.35 ml of guinea pig serum with strain LA-3399. Strain PD-05074 was completely resistant to 0.4 ml of human serum and 0.28 ml of guinea pig serum. The addition of 0.02 ml or less of a rabbit antiserum with a homologous agglutination titer of 1:320 to 0.3 ml of undiluted guinea pig serum as a complement source did not result in a detectable bactericidal effect against strain PD-05074. Although this antiserum was ineffective against the homologous organism, it showed evidence of bactericidal antibody against strain TIR-55. Homologous antisera and the heptavalent antiserum showed the presence of bactericidal antibody against strains TIR-59, TIR-43, TIR-55, TIR-60, 74C-1, and LA-3399. The tests with the second group of 16 strains against guinea pig serum gave essentially similar results ( Table 2 ). The strains showed wide variation in sensitivity to guinea pig serum, ranging from a 50% end point of 0.015 ml with strains TIR-24 and TIR-93 to greater than 0.4 ml for strains UI-24, BHK-19, VAD-1370, and BRK-4-11-2. These extreme values represent about a 30-fold variation.
Sensitivity to polymyxin, Whereas the seven different strains showed marked variation in sensitivity to normal human serum (30-fold), there was greater uniformity in their reaction to polymyxin (Table 1) . A positive correlation seemed to exist between sensitivity to serum and polymyxin, since strains isolated from patients with cystic fibrosis were extremely sensitive to normal serum. With 9 of 12 of these strains tested, the guinea pig serum 50% end point was less than 0.15 ml (Table 1 and 2). Although the precise role of resistance to the immune bactericidal reaction as a determinant of bacterial virulence is not known, these findings suggest that, in cystic fibrosis patients, infection may occur with relatively avirulent strains because of the peculiar host environment which protects the microbes against the bactericidal activity of plasma. Conversely, it is possible that the immune bactericidal reaction is depressed in cystic fibrosis patients. Bactericidal assays of the sera of these patients would be desirable to elucidate this point. Of the three strains isolated from wounds, two were resistant to the largest amount of serum tested (0.4 ml), but one strain, UI-10, was relatively sensitive (Table 2 ). This strain was extremely slow in attaining readable densities, but the relationship, if any, between its slow division rate and serum sensitivity is not known. Similarly, the five strains isolated from urine were very heterogeneous in serum sensitivity, ranging from 50% end points of 0.016 ml to greater than 0.4 ml. Four of the five strains, however, were relatively resistant, with end points of 0.17 ml or greater. In general, the strains isolated from patients with cystic fibrosis were considerably more sensitive to normal serum than the strains obtained from wounds or urine.
The experimental results with immune sera encourage the possible use of Pseudomonas vaccines. Homologous antisera and heptavalent antiserum gave evidence of bactericidal antibody activity against all of the strains tested except PD-05074, which was resistant to both normal and immune sera. Assuming that bactericidal antibody is associated with immunity against P. aeruginosa, it would seem that the heptavalent antigen used in this study or a similar preparation might be an effective vaccine, particularly against strains sensitive to the complement system. However, pooled human gamma globulin provided passive protection in mice, even against challenge with strain 28, now redesignated PD-05074 (6). In these experiments, cells may be involved in addition to humoral substances. In any event, it is conceivable that a multivalent vaccine might afford protection against most or all strains of Pseudomonas.
Finally, the reactivity of the PD-05074 antiserum against TIR-55, despite its lack of reactivity against the homologous organism, is interesting but not too surprising. Apparently, TIR-55 possesses a cross-reactive antigen with PD-05074. (Table 3) ; polymyxin, for example, is almost 3,000 times more potent than penicillin.
The primary damage to bacterial cells resulting from the action of polymyxin and of the complement system is a loss of permeability control (8) . Most of the Pseudomonas strains were relatively homogeneous in their sensitivity to polymyxin, in contrast to their marked variation in sensitivity to serum. Little or no association between a strain's sensitivity to the two bactericidal agents was found, despite the attack upon the cell membrane by both agents with a resulting loss of permeability control. Resistance to normal serum, however, may not reflect an inherent resistance of an organism to the complement system, but rather a lack of normal antibody in serum. However, strain PD-05074 was resistant to the complement system, even in the presence of an antiserum with a high agglutinin titer.
Previous work indicated that, when S. typhi Ty 2 or Paracolobactrum ballerup was cultivated at temperatures higher than 37 C, the organism became more susceptible to serum bactericidal action. This increased susceptibility was associated with the loss of the Vi antigen (10) . P. aeruginosa LA-3399 also became significantly more sensitive to normal serum when cultivated at 41 C rather than at 37 C ( (Table  3) . These experimental results suggest that fever in a host may not only aid the host's natural bactericidal mechanisms but also the bactericidal activity of deliberately administered drugs. Studies designed to elucidate the physiological changes in organisms that increase their susceptibility to antibiotics would be of value.
